Table 1.
Protocols selected as the most common choice
| Protocol/trial (% of responding clinicians selecting protocol/trial as most common choice) | ||||
|---|---|---|---|---|
| Adults with Ph − disease | Adults with Ph + disease | |||
| France | GRAALL 2014 | 50 | ALL GRAALLPHAG06/EWALL-PH–01 | 35 |
| Germany | GMALL 08 2013 | 65 | GMALL 08 2013 | 65 |
| Italya | GIMEMA LAL1913 | 42 | GIMEMA LAL1811 | 25 |
| Spain | PETHEMA LAL-AR/2011 | 57 | PETHEMA LAL PH–2008 | 59 |
| UK | UK ALL 14 | 70 | UK ALL 14 | 68 |
aUse of a range of GIMEMA protocols was reported for Italy, reflecting different populations (GIMEMA LAL1913, GIMEMA LAL1104, and GIMEMA LAL1308 for Ph − disease; GIMEMA LAL1811 and GIMEMA LAL1408 for Ph + disease)
ALL, acute lymphoblastic leukemia; Ph, Philadelphia chromosome translocation